drugset / Trial / NCT03412292
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).
Timeline
- Start
- 2018-08-01
- Primary completion
- 2022-11-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MAX-40279 | Unknown | 20 mg | Oral |
| Subject | MAX-40279 | Unknown | 40 mg | Oral |
| Subject | MAX-40279 | Unknown | 70 mg | Oral |
| Subject | MAX-40279 | Unknown | 100 mg | Oral |
| Subject | MAX-40279 | Unknown | 120 mg | Oral |